BioNTech appears undervalued. Like Moderna, it could flip the current market narrative through oncology efforts. But that's hardly the only thing that can move the stock higher.
Moderna, once left for dead as a company that had no real business outside of a declining Covid vaccine operation, has seen its stock nearly quadruple since mid August. After years of hoarding cash, it's investing in a vaccine that could prevent recurrence of melanoma and lung cancer. Millions of people have those types of cancer, and since insurers spend thousands per patient annually, revenue could total tens of billions. The total oncology industry brings in hundreds of billions yearly, according to Iqvia.
Enter BioNTech. The Mainz, Germany-based company had a surging Covid vaccine business which subsequently declined, has a stock price that lost the majority of its value from peaks, has almost $18 billion in net cash and equivalents, uses mRNA, and is investing in oncology. Sound familiar?
BioNTech has its own cancer pipeline that could spark significant gains for the stock. Even in the worst case scenario, it could become a special situation, undergoing wholesale changes that could unlock shareholder value. The company could be well over $30 billion soon, suggesting a $120 stock price, or a premium of about 37% from Wednesday's close of $87.65. The average analyst price target is $115.
The stock looks cheap on multiple levels. The first one that jumps out is its cash levels. Net cash comprises the vast majority of its $21.7 billion market capitalization. That's rare; most pharmaceutical companies have more debt than cash, and are currently valued on the basis that future cash flows will surge as new drugs come to market.
BioNTech's market cap- stripping out net cash- leaves just $3.7 billion worth of equity value from future cash flows, or 1.9 times the $1.8 billion in revenue analysts expect for the coming 12 months, according to FactSet. That's a significant discount to the State Street SPDR S&P Pharmaceuticals ETF's roughly four times sales.
So any positive oncology pipeline developments would spark large stock gains. Adding a few billion or more of sales from new drugs would do the trick if the market assigns a normal, pharma-like multiple to those revenue.
That puts the company's over 25 oncology drug candidates in focus. They're between phases 1 and 3 of trials. Many target rarer cancers, while others have wider oncology applications.
One is for pancreatic cancer. Over 500,000 people globally are diagnosed, according to the International Agency For Cancer Research, part of the World Health Organization. Phase 2 is under way.
The most important one is Pumitamig. An antibody rather than mRNA, it could treat multiple cancers; pancreatic, colorectal, liver, non-small cell lung, triple-negative breast cancer, among others.
"This would be a significant product, if successful," says Canaccord analyst John Newman.
Pumitamig could prove lucrative with its reach -- and more information about it is coming. BioNTech will present phase 3 trial data for a Pumitamig candidate that aims to treat breast cancer and other types in 2027. BioNTech and its partner Bristol Myers Squibb would split the profit. (Bristol Myers is a Barron's Investor Circle stock pick).
Pumitamig is key, partly because it won't fully compete with Moderna and Merck's cancer drug. That focuses on Melanoma and lung cancer, and while it has other applications, many don't interfere with Pumitamig's focus areas.
If the oncology pipeline doesn't bear fruit, the stock won't necessarily fall hard. The pipeline is essentially not reflected in the stock to begin with.
The main risk is the $1 billion-plus in annual cash burn from the over $2 billion research and development budget. Continued burn would reduce net cash, hurting the market cap. But cash burn would happen gradually, while other developments could support the stock.
Among those is the potential for an activist investor to come in. The market will first give management a chance on cancer, but activism isn't unthinkable if the pipeline falters after 2028 trial data.
To be sure, early private investor AT Impf GmbH, or Athos Family Office, owns 41% of the shares, while founder and departing CEO Ugur Sahin owns 16%. Both shareholders would have lots of voting power, should another shareholder push for change.
But maybe Sahin or Athos would vote in alignment with an activist for changes upon pipeline failures. After all, Sahin is leaving. Pharma veteran Guido Oelkers will replace him in February.
"One hundred percent -- the activist part could absolutely happen," says Jeffrey Walch, Bernstein Research analyst. "Someone could accumulate a lot of shares."
That someone could push for slightly less R&D, or cash flow-producing acquisitions. Walch says that, while activism currently remains theoretical, it would likely include a push for yet another management change.
New management could pivot the pipeline away from oncology if it disappoints. The mRNA technology can help treat other diseases.
"Is there some activist that is upset with the trajectory of the company and they want to bring in a new management team who they think is a better drug developer? That, I think, is reasonable," says Walch.
Walch isn't alone.
"If they don't have Pumitamig, then they really need to find something else," says Morningstar analyst Jay Lee. "Get new management in -- something along those lines probably needs to happen if Pumitamig is not it."
Another small probability is a buyout offer. One can only speculate, but battered stocks that haven't grown in recent years are often takeout candidates. BioNTech's mRNA could attract a bid from a pharmaceutical giant.
"It's not out of the realm of possibility," says John Newman, Canaccord analyst. "Is it possible at some point in the future maybe Bristol Myers takes a look at BioNTech? Sure."
Elsewhere, Pfizer partners with BioNTech for the Covid vaccine. Pfizer declined to comment. Bristol Myers didn't immediately respond to a request for comment.
To be clear, there are no rumors of a strategic buyer or activism. The analysts don't include these situations in their current theses. A couple small shareholders have activist histories. We, at Barron's, pose these possibilities as conceivable if oncology disappoints.
A BioNTech spokesperson told Barron's that Athos and Sahin currently plan to remain shareholders.
The point: shares are more than worth a bet, given the pipeline, or a special situation.
Join us for the next live Q&A: Hear from our stock pickers and technical analyst as we discuss the latest market developments -- and take your questions. Register here
Share your questions and thoughts in the "Conversation" section below to engage directly with the author and our community
Receive alerts about more content from this author by clicking "Follow" next to the author byline at top
Write to Jacob Sonenshine at jacob.sonenshine@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
By Jacob Sonenshine
BioNTech appears undervalued. Like Moderna, it could flip the current market narrative through oncology efforts. But that's hardly the only thing that can move the stock higher.
Moderna, once left for dead as a company that had no real business outside of a declining Covid vaccine operation, has seen its stock nearly quadruple since mid August. After years of hoarding cash, it's investing in a vaccine that could prevent recurrence of melanoma and lung cancer. Millions of people have those types of cancer, and since insurers spend thousands per patient annually, revenue could total tens of billions. The total oncology industry brings in hundreds of billions yearly, according to Iqvia.
Enter BioNTech. The Mainz, Germany-based company had a surging Covid vaccine business which subsequently declined, has a stock price that lost the majority of its value from peaks, has almost $18 billion in net cash and equivalents, uses mRNA, and is investing in oncology. Sound familiar?
BioNTech has its own cancer pipeline that could spark significant gains for the stock. Even in the worst case scenario, it could become a special situation, undergoing wholesale changes that could unlock shareholder value. The company could be well over $30 billion soon, suggesting a $120 stock price, or a premium of about 37% from Wednesday's close of $87.65. The average analyst price target is $115.
The stock looks cheap on multiple levels. The first one that jumps out is its cash levels. Net cash comprises the vast majority of its $21.7 billion market capitalization. That's rare; most pharmaceutical companies have more debt than cash, and are currently valued on the basis that future cash flows will surge as new drugs come to market.
BioNTech's market cap- stripping out net cash- leaves just $3.7 billion worth of equity value from future cash flows, or 1.9 times the $1.8 billion in revenue analysts expect for the coming 12 months, according to FactSet. That's a significant discount to the State Street SPDR S&P Pharmaceuticals ETF's roughly four times sales.
So any positive oncology pipeline developments would spark large stock gains. Adding a few billion or more of sales from new drugs would do the trick if the market assigns a normal, pharma-like multiple to those revenue.
That puts the company's over 25 oncology drug candidates in focus. They're between phases 1 and 3 of trials. Many target rarer cancers, while others have wider oncology applications.
One is for pancreatic cancer. Over 500,000 people globally are diagnosed, according to the International Agency For Cancer Research, part of the World Health Organization. Phase 2 is under way.
The most important one is Pumitamig. An antibody rather than mRNA, it could treat multiple cancers; pancreatic, colorectal, liver, non-small cell lung, triple-negative breast cancer, among others.
"This would be a significant product, if successful," says Canaccord analyst John Newman.
Pumitamig could prove lucrative with its reach -- and more information about it is coming. BioNTech will present phase 3 trial data for a Pumitamig candidate that aims to treat breast cancer and other types in 2027. BioNTech and its partner Bristol Myers Squibb would split the profit. (Bristol Myers is a Barron's Investor Circle stock pick).
Pumitamig is key, partly because it won't fully compete with Moderna and Merck's cancer drug. That focuses on Melanoma and lung cancer, and while it has other applications, many don't interfere with Pumitamig's focus areas.
If the oncology pipeline doesn't bear fruit, the stock won't necessarily fall hard. The pipeline is essentially not reflected in the stock to begin with.
The main risk is the $1 billion-plus in annual cash burn from the over $2 billion research and development budget. Continued burn would reduce net cash, hurting the market cap. But cash burn would happen gradually, while other developments could support the stock.
Among those is the potential for an activist investor to come in. The market will first give management a chance on cancer, but activism isn't unthinkable if the pipeline falters after 2028 trial data.
To be sure, early private investor AT Impf GmbH, or Athos Family Office, owns 41% of the shares, while founder and departing CEO Ugur Sahin owns 16%. Both shareholders would have lots of voting power, should another shareholder push for change.
But maybe Sahin or Athos would vote in alignment with an activist for changes upon pipeline failures. After all, Sahin is leaving. Pharma veteran Guido Oelkers will replace him in February.
"One hundred percent -- the activist part could absolutely happen," says Jeffrey Walch, Bernstein Research analyst. "Someone could accumulate a lot of shares."
That someone could push for slightly less R&D, or cash flow-producing acquisitions. Walch says that, while activism currently remains theoretical, it would likely include a push for yet another management change.
New management could pivot the pipeline away from oncology if it disappoints. The mRNA technology can help treat other diseases.
"Is there some activist that is upset with the trajectory of the company and they want to bring in a new management team who they think is a better drug developer? That, I think, is reasonable," says Walch.
Walch isn't alone.
"If they don't have Pumitamig, then they really need to find something else," says Morningstar analyst Jay Lee. "Get new management in -- something along those lines probably needs to happen if Pumitamig is not it."
Another small probability is a buyout offer. One can only speculate, but battered stocks that haven't grown in recent years are often takeout candidates. BioNTech's mRNA could attract a bid from a pharmaceutical giant.
"It's not out of the realm of possibility," says John Newman, Canaccord analyst. "Is it possible at some point in the future maybe Bristol Myers takes a look at BioNTech? Sure."
Elsewhere, Pfizer partners with BioNTech for the Covid vaccine. Pfizer declined to comment. Bristol Myers didn't immediately respond to a request for comment.
To be clear, there are no rumors of a strategic buyer or activism. The analysts don't include these situations in their current theses. A couple small shareholders have activist histories. We, at Barron's, pose these possibilities as conceivable if oncology disappoints.
A BioNTech spokesperson told Barron's that Athos and Sahin currently plan to remain shareholders.
The point: shares are more than worth a bet, given the pipeline, or a special situation.
Join us for the next live Q&A: Hear from our stock pickers and technical analyst as we discuss the latest market developments -- and take your questions. Register here
Share your questions and thoughts in the "Conversation" section below to engage directly with the author and our community
Receive alerts about more content from this author by clicking "Follow" next to the author byline at top
Comments